121 related articles for article (PubMed ID: 25873167)
1. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia.
Kühn MW; Armstrong SA
Cancer Cell; 2015 Apr; 27(4):431-3. PubMed ID: 25873167
[TBL] [Abstract][Full Text] [Related]
2. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
3. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.
Aguilar A; Zheng K; Xu T; Xu S; Huang L; Fernandez-Salas E; Liu L; Bernard D; Harvey KP; Foster C; McEachern D; Stuckey J; Chinnaswamy K; Delproposto J; Kampf JW; Wang S
J Med Chem; 2019 Jul; 62(13):6015-6034. PubMed ID: 31244110
[TBL] [Abstract][Full Text] [Related]
5. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
6. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
[TBL] [Abstract][Full Text] [Related]
7. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
[TBL] [Abstract][Full Text] [Related]
8. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
11. Challenges and opportunities in targeting the menin-MLL interaction.
Cierpicki T; Grembecka J
Future Med Chem; 2014 Mar; 6(4):447-62. PubMed ID: 24635524
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.
Murai MJ; Chruszcz M; Reddy G; Grembecka J; Cierpicki T
J Biol Chem; 2011 Sep; 286(36):31742-8. PubMed ID: 21757704
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide.
Yue L; Du J; Ye F; Chen Z; Li L; Lian F; Zhang B; Zhang Y; Jiang H; Chen K; Li Y; Zhou B; Zhang N; Yang Y; Luo C
Org Biomol Chem; 2016 Sep; 14(36):8503-19. PubMed ID: 27541268
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
Grembecka J; Belcher AM; Hartley T; Cierpicki T
J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
[TBL] [Abstract][Full Text] [Related]
15. Menin as a hub controlling mixed lineage leukemia.
Thiel AT; Huang J; Lei M; Hua X
Bioessays; 2012 Sep; 34(9):771-80. PubMed ID: 22829075
[TBL] [Abstract][Full Text] [Related]
16. Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface.
Li L; Zhou R; Geng H; Yue L; Ye F; Xie Y; Liu J; Kong X; Jiang H; Huang J; Luo C
Bioorg Med Chem Lett; 2014 May; 24(9):2090-3. PubMed ID: 24709560
[TBL] [Abstract][Full Text] [Related]
17. The role of menin in hematopoiesis.
Maillard I; Hess JL
Adv Exp Med Biol; 2009; 668():51-7. PubMed ID: 20175452
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Inhibitors Targeting the Menin-Mixed Lineage Leukemia Interface Using Pharmacophore- and Docking-Based Virtual Screening.
Xu Y; Yue L; Wang Y; Xing J; Chen Z; Shi Z; Liu R; Liu YC; Luo X; Jiang H; Chen K; Luo C; Zheng M
J Chem Inf Model; 2016 Sep; 56(9):1847-55. PubMed ID: 27513308
[TBL] [Abstract][Full Text] [Related]
19. Interaction of MLL amino terminal sequences with menin is required for transformation.
Caslini C; Yang Z; El-Osta M; Milne TA; Slany RK; Hess JL
Cancer Res; 2007 Aug; 67(15):7275-83. PubMed ID: 17671196
[TBL] [Abstract][Full Text] [Related]
20. A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia.
Ozyerli-Goknar E; Nizamuddin S; Timmers HTM
ChemMedChem; 2021 May; 16(9):1391-1402. PubMed ID: 33534953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]